HDL and SARS CoV-2: emerging theragnostic implications

Alankrita Rani; Julia T Stadler; Gunther Marsche

doi:10.1016/j.molmed.2024.02.001

HDL and SARS CoV-2: emerging theragnostic implications

Trends Mol Med. 2024 Mar 1:S1471-4914(24)00026-1. doi: 10.1016/j.molmed.2024.02.001. Online ahead of print.

Authors

Alankrita Rani¹, Julia T Stadler¹, Gunther Marsche²

Affiliations

¹ Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Styria, Austria.
² Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Styria, Austria; BioTechMed-Graz, Mozartgasse 12/II, 8010 Graz, Styria, Austria. Electronic address: gunther.marsche@medunigraz.at.

PMID: 38431503
DOI: 10.1016/j.molmed.2024.02.001

Abstract

High-density lipoproteins (HDLs) are complex particles with multiple functions. They are thought to have evolved as part of the body's innate defense system against infection. Recent research suggests that HDL levels influence susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the severity of associated complications, making it a promising target for therapeutic intervention.

Keywords: SARS-CoV-2;apolipoprotein mimetics; anti-inflammatory; antiviral; high-density lipoprotein.